Moderna, Inc. (MRNA)
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Learn moreNews headlines Moderna (MRNA) is navigating a complex landscape with a recent patent dispute settlement and a shift towards individualized cancer therapies. Despite a significant share price increase over the past year, the company faces challenges with ongoing losses and regulatory hurdles affecting its growth narrative.
Moderna (MRNA) is navigating a complex landscape with a recent patent dispute settlement and a shift towards individualized cancer therapies. Despite a significant share price increase over the past year, the company faces challenges with ongoing losses and regulatory hurdles affecting its growth narrative.
- Previous Close
- Open
- Bid 49.87 x 400
- Ask 50.19 x 400
- Day's Range
- 52 Week Range
- Volume
- Avg. Volume
- Market Cap (intraday)
- Beta (5Y Monthly) 1.35
- PE Ratio (TTM)
- EPS (TTM)
- Earnings Date (est.) Apr 30, 2026
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provides oncology therapeutics, such as intismeran autogene, cancer antigen therapy, t-cell engager, and cell therapy enhancer; and rare disease products, including propionic and methylmalonic acidemia, and cystic fibrosis. It has strategic alliances and collaborations with Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; immatics N.V.; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
www.modernatx.com
Cathie Wood Adds 48K Shares to This Under-the-Radar Growth Play
MRNA, SRPT, and KRYS Phase 3 Data Will Shape XBI’s 2026 Performance
Moderna’s Diverging Flu Vaccine Rulings May Shift mRNA Growth Story
Why Is Alkermes (ALKS) Down 2.6% Since Last Earnings Report?
Trailing total returns as of 4/1/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
Q1
FY25
Q2
FY25
Q3
FY25
Q4
FY25
- Strong Buy
- Buy
- Hold
- Underperform
- Sell
Market Cap
20.15B
Enterprise Value
15.65B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
10.28
Price/Book (mrq)
2.33
Enterprise Value/Revenue
8.14
Enterprise Value/EBITDA
--
Profitability and Income Statement
Profit Margin
-145.16%
Return on Assets (ttm)
-14.51%
Return on Equity (ttm)
-28.87%
Revenue (ttm)
1.94B
Net Income Avi to Common (ttm)
-2.82B
Diluted EPS (ttm)
-7.26
Balance Sheet and Cash Flow
Total Cash (mrq)
5.8B
Total Debt/Equity (mrq)
15.09%
Levered Free Cash Flow (ttm)
-1.33B
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
RatingPrice TargetMorningstar• yesterdayModerna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
RatingPrice TargetMorningstar• 28 days agoModerna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
RatingPrice TargetMorningstar• last monthModerna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
RatingPrice TargetMorningstar• last month